Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of investors of Insys Therapeutics, Inc. (“Insys” or the “Company”) (NASDAQ:INSY) concerning possible violations of federal securities laws. The investigation focuses on certain statements issued by Insys concerning the Company’s operations and financial prospects. Insys is a development stage company engaged in the development of pharmaceutical products that target the unmet needs of cancer patients, with a focus on cancer-supportive care. The Company’s product Subsys is a proprietary sublingual fentanyl spray for treatment of pain in opioid-tolerant cancer patients. The investigation is related to the Company’s December 12, 2013, disclosure that the Company has received a subpoena from the Office of Inspector General of the Department of Health and Human Services (HHS), in connection with an investigation of potential violations involving HHS programs. According to a Company-issued press release, “the subpoena requests documents regarding Subsys®, including Insys' sales and marketing practices relating to this product.” If you purchased Insys shares, if you have information or would like to learn more about these claims, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, Toll Free at (888) 638-4847, or by email to email@example.com, or visit our website at www.howardsmithlaw.com.